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Abstract 
Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide, and genetic 
investigations into the human lipidome may provide insight into CVD risk.  The aim of this study was to 
estimate the heritability of circulating lipid species and their genetic correlation with CVD traits.    
Methods: Targeted lipidomic profiling was performed on 4492 participants from the Busselton Family 
Heart Study to quantify the major fatty acids of 596 lipid species from 33 classes. We estimated narrow-
sense heritabilities of lipid species/classes, and their genetic correlations with eight CVD traits – body mass 
index, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, triglycerides, 
total cholesterol, waist-hip-ratio, systolic blood pressure, and diastolic blood pressure.   
Results: We report heritabilities and genetic correlations of new lipid species/sub-classes, including 
acylcarnitine, ubiquinone, sulfatide, and oxidized cholesteryl esters. Over 99% of lipid species were 
significantly heritable (h2:0.06-0.50) and all lipid classes were significantly heritable (h2:0.14-0.50). The 
monohexosylceramide and acylcarnitine classes had the highest median heritabilities (h2=0.43).  The 
largest genetic correlation was between clinical triglycerides and total diacylglycerol (rg=0.88). We 
observed novel positive genetic correlations between clinical triglycerides and phosphatidylglycerol 
species (rg: 0.64-0.82), and HDL-C and alkenylphosphatidylcholine species (rg:0.45-0.74). Overall, 51% of 
the 4768 lipid species-CVD trait genetic correlations were statistically significant after correction for 
multiple comparisons.  
Conclusion: This is the largest lipidomic study to address the heritability of lipids, and their genetic 
correlation with CVD traits. Future work includes identifying putative causal genetic variants for lipid 
species and CVD using genome-wide single nucleotide polymorphism and whole genome sequencing data.    
Keywords: lipidomics, cardiovascular disease, lipids, genetic correlation, heritability 
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Introduction  
Cardiovascular disease (CVD) is the leading cause of death globally, accounting for approximately 31% of 
all deaths in 2015 (1). Cardiometabolic traits associated with CVD include the standard lipid profile 
(‘clinical lipids’), such as elevated low density lipoprotein cholesterol (LDL-C), triglycerides, and lowered 
high density lipoprotein cholesterol (HDL-C), and other factors such as elevated body mass index (BMI), 
systolic blood pressure (SBP), and diastolic blood pressure (DBP) (2). These traits are heritable, with the 
heritability of each trait dependent on the study type and sample used to measure heritability (3). Typical 
reported heritabilities for clinical lipid traits are in the range of 0.30 to 0.70 (4-9), while blood pressure and 
obesity-related traits tend to vary between 0.20 and 0.50 (4-8, 10).  
 
Clinical lipid measures such as total cholesterol, LDL-C and HDL-C reflect the cholesterol component of 
the lipoprotein particles, which are complex mixtures of phospholipids, sphingolipids, free cholesterol, 
cholesteryl esters and triglycerides (referred to as triacylglycerol species in the mass spectrometric 
measurements), together with a range of proteins (11). These lipid classes contain potentially thousands of 
individual molecular species that make up the human lipidome - which can now be measured using 
established low-cost, high-throughput methods (12). Lipids are transported through plasma as lipoproteins 
for exchange between the liver, intestine and peripheral tissues. Their composition and abundance are 
likely to reflect underlying metabolic processes influenced by the environment, diet, and genetics (11). The 
individual species comprising the lipidome may represent novel predictors of CVD risk, particularly if 
measured in longitudinal cohort studies where causality may potentially be inferred (11, 13). Owing to 
their close proximity to an individual’s metabolic state, genetic investigations into these lipid species may 
provide insight into CVD risk and prediction - above that already identified through the genetic analysis of 
the composite clinical lipid measures. This is particularly the case for lipid species that are genetically 
correlated with disease-related traits as the search for pleotropic clues can be restricted to the more 
informative species (i.e. those that are heritable and genetically correlated).  
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Associations between the circulating lipidome and CVD traits have provided insight into CVD aetiology 
and identified novel biomarkers. Meikle et al. identified 13 lipid classes and 102 lipids associated with 
stable coronary artery disease (CAD) compared to healthy controls (14). In a more recent study, nine lipid 
classes/subclasses and 113 lipid species from the apoA fraction, and seven classes/subclasses and 113 lipid 
species from plasma were associated with unstable CAD (compared to stable CAD) (15). In the Malmo 
Diet and Cancer study, incident cardiovascular events were marginally associated with lipid species 
belonging to the lysophosphatidylcholine (LPC), sphingomyelin (SM) and triacylglycerol (TG) lipid 
classes (16). Ganna et al. found significant associations between incident coronary heart disease and 32 
metabolites, five of which were also associated in an independent cohort (17). After adjustment for 
traditional CVD risk factors, the addition of lipid species to a base model predicting CVD events 
marginally improved for CVD events (C-statistic increased from 0.68 to 0.70), and CVD deaths (C-statistic 
increased from 0.74 to 0.76) (13) . Similar results were seen in a study of 5991 individuals from a 
population-based study, with the inclusion of seven lipid species in a traditional risk factor model 
improving the C-statistic by 0.025  and 0.054 for CVD events and CVD death, respectively (18).   
 
Numerous studies have estimated the heritability of the lipidome and its association and/or genetic 
correlation with CVD traits. In a study of Mexican Americans from the San Antonio Family Heart Study 
(19), all 319 lipid species were significantly heritable, with a median heritability of 0.37. This study also 
identified lipid species clustered associated with risk of cardiovascular death, and other CVD-related risk 
factors, such as obesity, type 2 diabetes, and higher triglycerides. In a more recent study of  2,181 
individuals, Tabassum et al.(20) estimated SNP-based heritabilities of 141 lipid species ranging between 
0.10 to 0.54. Strong genetic correlations were observed between triacylglycerol (TG) and diacylglycerol 
(DG) lipid classes and the clinical lipid measure of triglycerides (average rg=0.88). Most recently, 
Demirkan et al. (21) examined the genetic correlation between 90 lipid species from triacylglycerol (TG), 
sphingomyelin (SM), phosphatidylcholine (PC), alkylphosphatidycholine [PC(O)], lysophosphatidycholine 
(LPC), phosphatidylethanolamine (PE) and alkylphosphatidylethanolamine [PE(O)]  classes and identified 
genetic correlations between lipid species and clinical lipids (i.e. triglycerides, LDL-C, HDL-C), total body 
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fat percentage and BMI. These studies indicate that the plasma lipidome is heritable and highlight the 
genetic pleiotropy that exists between the plasma lipidome and CVD traits. 
 
The aim of this study was to estimate the heritability of the human lipidome and the genetic correlation 
between lipid classes and species with CVD traits using our expanded lipidomic profile (with more specific 
lipid species and new lipid classes) of the Busselton Family Heart Study.   
 
Materials and Methods 
Study population  
Participants (n=4,492) studied were taken from the 1994/95 survey of the original participants of the long-
running epidemiological study, the Busselton Health Study, for whom genome-wide single nucleotide 
polymorphism (SNP) data, extensive phenotype data, and blood serum were available. The Busselton 
Health Study is a community-based study in Western Australia that includes both related and unrelated 
individuals (predominantly of European ancestry), and has been described in more detail elsewhere (22-
24). Informed consent was obtained from all participants and the 1994/95 health survey was approved by 
the University of Western Australia Human Research Ethics Committee (UWA HREC). The current study 
– the Busselton Family Heart Study - was approved by UWA HREC.  
 
Serum lipidomic profiling 
Targeted lipidomic profiling was performed in positive-ion mode using electrospray ionization-tandem 
mass spectrometry to quantify the major fatty acids of 596 lipid species from 33 lipid classes, from blood 
serum. Positive-ion mode only was selected to minimise the time required for analysis of each sample, 
while still providing good coverage of the lipidome (25). Profiling was performed at the Metabolomics 
Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria.  Serum lipids were isolated using a 
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single phase butanol:methanol (BuOH:MeOH) extraction (26) and quantified by liquid chromatography-
tandem mass spectrometry as previously described (25). Briefly, serum samples (10 µL) were placed into a 
randomised order, with blank and pooled quality control samples placed every 20 and 10 serum samples, 
respectively. Serum aliquots were extracted in a single-phase extraction with the addition of 100ul of 
BuOH:MeOH (1:1), containing a mix of 18 non-physiological or stable isotope-labelled lipid standards 
between 10 and 10000 pmol each. Lipid analysis was performed by liquid chromatography electrospray 
ionisation-tandem mass spectrometry using an Agilent 1290 HPLC coupled to an Agilent 6490 triple 
quadrupole mass spectrometer. The ion source was operated in positive ionization mode, with conditions: 
gas temperature 150°C, gas flow 17 L/min, nozzle pressure 20 psi, sheath gas temperature 200°C, sheath 
gas flow 10L/min, capillary voltage 3500V, nozzle voltage 1000V. Liquid chromatography was performed 
on a Zorbax Eclipse Plus C18, 1.8 um, 100 x 2.1mm column (Agilent Technologies). Solvents consisted of 
water:acetonitrile:isopropanol containing 10 mM ammonium formate (solvent A, 50:30:20; solvent B, 
1:9:90). The column was heated to 60°C and the auto sampler regulated to 25°C. Lipid extracts (1uL) were 
injected and separated under gradient conditions using a flow rate of 400uL/min: 0 minutes, 10% B; 2.7 
minutes, 45% B; 2.8 minutes, 53% B; 9 minutes, 65% B; 9.1 minutes, 89% B; 11 minutes, 92% B; 11.1 
minutes, 100% B; 11.9 minutes, 100% B; 12.8 minutes, 10% B; 12.9 minutes, 10% B (flow rate 
600uL/min); 13.9 minutes, 10% B (flow rate 600uL/min); 14 minutes, 10% B (flow rate 400uL/min); held 
at 10%B and 400ul/min until the next injection at 16.2 minutes. The first minute and last three minutes of 
each analytical run are diverted to waste.  
 
A total of 497 transitions, representing 596 lipid species, were measured using dynamic multiple reaction 
monitoring (dMRM), where data was collected during a retention time window specific to each lipid 
species. Raw mass spectrometry data was analysed using Mass Hunter Quant B08 (Agilent Technologies). 
Lipid concentrations were calculated by relating the area under the chromatographic peak for each lipid 
species to the corresponding internal standard. Correction factors were applied to adjust for differences in 
response factors, where these were known (25).  
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Phenotypic variables 
Details of the Busselton Health Study data collection have been published previously (27). For this study, 
we examined eight CVD phenotypic variables: HDL-C, LDL-C, triglycerides, total cholesterol, SBP, DBP, 
BMI, and waist-hip ratio (WHR). Serum cholesterol and triglycerides were calculated by standard 
enzymatic methods on a Hitachi 747 (Roche Diagnostics, Sydney, Australia) from fasting blood collected 
in 1994/95.  HDL-C was determined on a serum supernatant after polyethylene glycol precipitation using 
an enzymatic cholesterol assay and LDL-C was estimated using the Friedewald formula (28). Five-minute 
resting SBP and DBP were used. Height and weight (used to calculate BMI) were collected from 
participants at time of interview (1994/95). WHR was calculated as waist circumference (cm) / hip 
circumference (cm). Use of antihypertensive and lipid-lowering medications were collected at interview 
(1994/95).  
 
Genotype data 
Genotyping was performed on the Illumina Human 610K Quad-Bead Chip (Illumina Inc., San Diego, CA, 
USA) at the Centre National de Genotypage in Paris, France (n=1468), and on the Illumina 660 W Quad 
Array Bead Chip (Illumina Inc., San Diego, CA, USA) at the PathWest Laboratory Medicine WA 
(Nedlands, WA, Australia (n=3428). Complete linkage clustering based on pairwise identity by state 
distance in PLINK (29) showed no batch effects, therefore the batches were merged.  
Standard genotype data quality control was performed (described in further detail elsewhere (24) ). Briefly, 
we excluded SNPs with: call rates < 95%, minor allele count < 10, and deviations from Hardy–Weinberg 
equilibrium (p < 5.0 × 10−4). Individuals were excluded if: > 3% of SNP data were missing (n = 11), 
reported sex did not match genotyped sex (n = 48), duplicates (n = 123), missing phenotype data (n = 11), 
or >5 standard deviations above/below mean heterozygosity (n=28). Individuals with non-European 
ancestry (n=4) were also excluded.  
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Statistical Analyses 
We first used the general linear mixed effects model incorporated in the Sequential Oligogenic Linkage 
Analysis Routines (SOLAR) (30) to estimate the narrow-sense heritabilities of lipid classes (n=33), lipid 
species (n=596), and eight CVD traits: HDL-C, LDL-C, triglycerides, total cholesterol, SBP, DBP, BMI and 
WHR. SOLAR uses a variance-component method to partition observed covariance between individuals into 
genetic and environmental components. Heritability is defined as the variance in the trait due to additive 
genetic effects divided by the sum of the additive genetic effects and the random (unmeasured) 
environmental effects. The null hypothesis of no heritability (h2=0) was tested by comparing the log 
likelihood for the full model (with the GRM) and the reduced model (without the GRM), using likelihood 
ratio tests. Twice the difference in log-likelihoods of these models was distributed as a χ2 random variable 
with 1 degree of freedom. 
 
Genetic correlations between lipid classes/species and eight CVD traits were calculated in SOLAR. Lipid 
classes were defined as the sum of the lipids within each class (i.e. total lipid abundance for each class). 
Genetic correlations were estimated using a variance components model to partition the phenotypic 
correlation between the traits into proportion of variability due to shared genetic effects, (ρg) and the 
proportion of variability due to shared environmental effects. The null hypothesis of no genetic correlation 
(rg=0) was tested by comparing the log likelihood for the full model (with the GRM) and the reduced 
model (without the GRM), using likelihood ratio tests.  
 
All heritability and genetic correlation analyses included a genetic relatedness matrix (GRM), to exploit 
both known and unknown relatedness in the sample. We estimated empirical kinship probabilities between 
pairs of individuals from all genome-wide SNP data using Linkage Disequilibrium Adjusted Kinships 
(LDAK) software (31), as described previously (24), to form the GRM. Any value of kinship in the GRM 
less than 0.05 was set to zero to minimise potential bias from using both closely and distantly related 
individuals. Using this method, heritability estimates derived from SNP data have been shown to be similar 
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to those obtained from using identity-by-descent measures from pedigrees with known pedigree structures 
(9).   
 
Rank-based inverse normal transformed residuals were used in all analyses.  All analyses included 
adjustments for age, sex, age2, and their interactions, age*sex and age2*sex. Adjustment for age and sex 
were included in heritability and genetic correlation analyses to estimate the additive genetic effects of 
lipid classes/species and CVD traits after accounting for these covariates. In addition, interaction terms 
were included as the relationship between outcomes (lipid classes/species and CVD traits) and age was 
different between men and women (age*sex interaction). We also identified that the relationship between 
outcomes and age was not linear, hence the inclusion of age2 and the age2*sex interaction. In our 
heritability and genetic correlation analyses, these interactions consistently showed p-values < 0.05. For 
individuals taking antihypertensive medications (n=507) their SBP and DBP measures were increased by 
10 mmHg and 5 mmHg, respectively. In addition, lipid measures were corrected by the use of lipid-
lowering medications, by matching individuals taking lipid-lowering medication (n=108) and individuals 
not taking medication on age, sex and BMI and calculating a multiplicative correction factor. The resulting 
correction factors were as follows: HDL-C (1.068), LDL-C (1.123), total cholesterol (1.059), triglycerides 
(1.138), and lipid species (1.234). Sensitivity analysis (results not shown) indicated no marked change in 
heritability or genetic correlation estimates, compared to excluding either these 108 individuals or using 
unadjusted measures. Only individuals with genotype, lipidomic, and phenotype data were included for 
analysis (n=4492). Manipulation of data and creation of residuals was performed in R 3.5.1 (32).  
 
 
The false discovery rate (33) was used to correct for multiple testing, with q<0.05 considered statistically 
significant. 
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Results 
Heritability  
Table 1 shows the study characteristics for the full cohort (n=4,492).  The average age of the study 
participants was 50.8 years, with mean BMI of 26.04. All CVD traits were significantly heritable (all 
q<0.05) (Table 1). The most heritable CVD trait was HDL-C (h2=0.59, q=7.2 x 10-61) and the least 
heritable was WHR (h2=0.25, q=2.0 x 10-15).   
 
 
All lipid classes were significantly heritable (q<0.05; Table 2). Heritabilities ranged from 0.14 (oxidized 
cholesteryl esters [oxCE]) to 0.50 (monohexosylceramide [HexCer]).  The estimates of these class totals 
and their concentration are shown in Figure 1. The median heritability was 0.34. 
 
Over 99% of lipid species were significantly heritable (q<0.05; Supplementary Table 1). Significant 
heritabilities ranged from 0.06 (PE(36:0); SE=0.03; q=0.04) to 0.50 (AC(16:1); SE=0.03; q=2.3 x 10-52). 
The median heritability was 0.31 (interquartile range=0.09). Overall, the classes acylcarnitine (AC) and 
monohexosylceramide (HexCer) had the highest median lipid species heritability of 0.43, and 
phosphatidylserine (PS) had the lowest median lipid species heritability of 0.16 (Figure 2).  
 
Genetic Correlation 
Genetic correlations between the lipid classes (sum of the lipid species within each class) and CVD traits 
are presented in Figure 3 (see Supplementary Table 2 for further detail).  Approximately 57% of genetic 
correlations were statistically significant (q<0.05). The largest genetic correlation was observed between 
the clinical lipid triglycerides and diacylglycerol (DG) (rg=0.89, SE=0.02; q=3.9x10
-22). Diacylglycerol 
(DG) and alkylphosphatidycholine [PC(O)] were genetically correlated with all CVD traits, and 
alkenylphosphatidylcholine [PC(P)] was genetically correlated with all CVD traits, except for DBP. LDL-
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C was genetically correlated with all lipid classes (rg range: 0.13 - 0.82), apart from phosphatidylserine 
(PS). In fact, phosphatidylserine (PS) was not genetically correlated with any CVD trait. Similarly, HDL-C 
was genetically correlated (rg range: -0.42 - 0.69) with all lipid classes, besides phosphatidylserine (PS) and 
acylcarnitine (AC). 
 
We also investigated the genetic correlations between individual lipid species and CVD traits, identifying 
where class correlations were driven by specific lipid species (Figure 4). Overall, 51% of the 4768 pairwise 
lipid species-CVD trait genetic correlations were statistically significant (q<0.05; Supplementary Table 3). 
All lipid classes had at least one species significantly genetically correlated with one CVD trait. Additionally, 
we observed large heterogeneity in genetic correlations within each class. The largest genetic correlations 
were between triglycerides and members of the diacylglycerol (DG) class (rg range: 0.47-0.89; q<4.1x10
-9). 
Three phosphatidylserine (PS) lipid species showed significant genetic correlations with LDL-C (PS(40:6), 
rg=0.32), total cholesterol (PS(40:6), rg=0.37; PS(40:5), rg=0.28; PS(36:1), rg=0.37), and BMI (PS(36:1), 
rg=0.22), while the class total showed no significant genetic correlations with any trait. Overall, the clinical 
lipids total cholesterol and LDL-C were the most consistently genetically correlated CVD traits, showing 
significant genetic correlations with 565 (94.8%) and 554 (92.9%) lipid species, respectively. 
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Discussion 
The current study provides evidence to support the role of additive genetic effects (significant 
heritabilities) in lipid species concentrations and the presence of genetic pleiotropy (shared genes) between 
these lipid species and CVD traits. This is the largest lipidomic study to address the heritability of lipids. 
The fine detail of our lipidomic profiling provides the opportunity to assess heritability not only at the lipid 
class level, but also to assess how the fatty acid composition affects heritability and genetic correlations 
with CVD risk factors.  These data will become an important resource as we seek to better understand the 
relationship between genetic and environmental risk with CVD, both of which are partially mediated 
through lipid metabolism. In this paper we report three important findings: first, we have shown that the 
human lipidome (both lipid species and lipid classes) is significantly heritable. Herein, we report the 
heritabilities for the largest number of lipid species to date (596 species from 33 lipid classes) in the largest 
sample of individuals (n=4492) to date. Second, we have identified lipid classes and lipid species 
genetically correlated with CVD traits. Third, we have replicated previous studies showing CVD traits are 
heritable. 
 
The range of lipid species heritabilities (h2: 0.06 to 0.50) observed in this study for lipid species and classes 
was comparable to that of earlier studies with estimates ranging from 0.09 to 0.60 (19, 20). This highlights 
and supports the role of additive genetic effects on lipid species levels, rather than only the effect of dietary 
intake or environmental factors.  
 
Strong positive genetic correlations between the clinical measure of triglycerides and the mass 
spectrometric measure of triacylglycerol (TG) and diacylglycerol (DG) lipid classes were similar to those 
identified previously (20, 21). In addition, we also observed a novel strong positive genetic correlation 
between the clinical lipid triglycerides and phosphatidylglycerol (PG) species (rg: 0.64 to 0.82). A novel 
strong positive genetic correlation was also observed between HDL-C and species within the 
alkenylphosphatidylcholine [PC(P)] class. Interestingly, HDL-C showed stronger positive correlations with 
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lipid classes containing ether (O) or vinyl-ether (P) bonds. Genetic correlations between the less 
unsaturated/shorter chain species and HDL-C were stronger than those with the highly unsaturated species. 
For example, the median genetic correlation with HDL-C within the alkenylphosphatidylcholine [PC(P)] 
class was 0.57, compared to 0.46 in the alkylphosphatidylcholine [PC(O)] class and 0.42 in the 
phosphatidylcholine (PC) class. Similarly, the median genetic correlation with HDL-C within the 
alkenylphosphatidylethanolamine [PE(P)] class was 0.45, compared to 0.43 in the 
alkylphosphatidylethanolamine [PE(O)] class and 0.17 in the phosphatidylethanolamine (PE) class. We 
also observed marked differences in genetic correlations between lipids in the phospholipid classes 
phosphatidylcholine (PC) and sphingomyelin (SM). For example, the median genetic correlation between 
LDL-C and lipid species in the sphingomyelin (SM) class was 0.47 (range: 0.30 to 0.67), compared to 0.27 
(range: 0.14 to 0.63) in the phosphatidylcholine (PC) class; the significant genetic correlations were always 
positive. However, 96% (25/26) of significant genetic correlations between lipids in the sphingomyelin 
(SM) class and triglycerides were negative, while only 35% (6/17) of significant genetic correlations 
between phosphatidylcholine (PC) lipids and triglycerides were negative. This is interesting as structurally 
these lipid classes are similar, in that they both contain a phosphorylcholine head group. However, unlike 
the sphingomyelin that contain only saturated and monounsaturated acyl chains, the phosphatidylcholine 
(PC) contain many species of polyunsaturated acyl chains and it appears that these species may drive the 
positive association with triglycerides. 
 
While genetic correlations between the human lipidome and lipid concentrations may not be surprising, we 
also identified genetic correlations between lipid classes and individual lipid species and measures of 
obesity (WHR and BMI) and blood pressures. A recent study of 5,537 participants from three Dutch 
population-based cohorts examined  90 plasma lipids and failed to identify any significant genetic 
correlations between blood pressure or WHR, but did observe several associations with BMI (21). In the 
current study, lipid species within the diacylglycerol (DG), phosphatidylcholine (PC), 
alkylphosphatidycholine [PC(O)], alkenylphosphatidylcholine [PC(P)], sphingomyelin (SM) and 
triacylglycerol (TG) classes showed the most consistent genetic correlations with WHR and BMI 
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(Supplementary Figure 1), with some species from phosphatidylcholine (PC) and sphingomyelin (SM) 
classes genetically correlated with BMI in an earlier study (21). Compared to the previous study, the 
lipidomic methodology in the current study allowed greater specificity of individual lipid species. In 
addition, Linkage Disequilibrium Score Regression is known to be less powerful than variance-component 
methods used in the current study (34). In general, species within classes showed consistent directions of 
genetic correlations with BMI and WHR (for example, all significant genetic correlations between sulfatide 
(Sulf) species and BMI and WHR were negative, while all significant genetic correlations between 
acylcarnitine (AC) species were positive).  
 
However, in the current study some lipid species within the sphingomyelin (SM), phosphatidylcholine 
(PC), lysophosphatidycholine (LPC), lysoalkylphosphatidylcholine  [LPC(O)], phosphatidylethanolamine 
(PE), and ceramide [Cer(d)] classes were positively genetically correlated with BMI/WHR, while others 
were negatively genetically correlated with WHR/BMI, although no lipid species within any class was 
positively genetically correlated with WHR, and negatively genetically correlated with BMI, or vice versa 
(Supplementary Figure 2). These differences are interesting, as they highlight that even within lipid 
classes, lipid species are genetically diverse, and may not share genes consistently with both WHR and 
BMI (both correlated traits). These genetic correlations between lipid species and non-lipid CVD traits 
indicate there are potentially pleiotropic genes that effect both lipid species and non-lipid CVD traits.  
 
Finally, we have replicated previous studies showing CVD traits are heritable with our heritability 
estimates (h2: 0.25 to 0.59) comparable to those published previously in a larger sample of the Busselton 
Family Heart Study (24) and in earlier, independent studies of CVD traits (4-10).  
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Limitations of the Study 
There are several potential limitations in our study. First, our study cohort comprised individuals with 
European ancestry and therefore these findings may not be generalizable to other ethnic populations. 
However, the heritability estimates observed in this study are comparable to an earlier study of Mexican-
Americans (19).  Second, lipid measures used within this study were measured only once, and therefore the 
lipid levels analysed represent a snapshot in time and as such may be influenced by environmental factors 
that may also cluster within families, such as seasonal variations, illness, diet and other lifestyle factors, 
that we were unable to take into account (35). Repeated lipid measures may result in less within-person 
variability; however, these are not available for this cohort. Third, serum samples were collected during the 
1994/95 BHS survey and kept at -80 degrees until processing. Although the stability of lipid metabolites 
has generally been shown to be robust to long-term storage, minor alterations have been previously 
reported (36, 37). However, as samples were collected at the same time point, any changes should be 
consistent between the serum samples and so will likely have minimal effect on our analyses. Finally, 
while we have identified the possibility of pleiotropic genes associated with the human serum lipidome and 
CVD traits, we have not identified specific genetic variants or genes, which is a logical next step in 
attempting to understand the shared genetic aetiology between the human lipidome and CVD traits. This 
will be the subject of future analyses.   
In summary, we have shown that the human lipidome is heritable and genetically correlated with CVD 
traits. We have identified novel intermediate lipid endophenotypes that are genetically correlated with 
CVD traits and due to their shared genetic aetiology, genetic dissection of these lipidome endophenotypes 
may help to identify causal genetic variants for CVD. Future work involves the analysis of genome-wide 
SNP and whole-genome sequence data in this cohort.  
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Tables 
Table 1: Characteristics of study population and heritability of CVD traits 
 
Mean (SD) 
 
 n=4492 
h2 (SE) h2 p-value 
   
 
h2 q-value 
Age, years 50.83 (17.37) - - - 
BMIa, kg/m2 26.04 (4.23) 0.46 (0.04) 5.9 x 10-42 1.2 x 10-41 
WHRa 0.85 (0.07) 0.25 (0.03) 2.0 x 10-15 2.0 x 10-15 
HDL-Cb, mmol/L 1.39 (0.39) 0.59 (0.03) 1.8 x 10-61 7.2 x 10-61 
LDL-Cb, mmol/L 3.60 (1.00) 0.52 (0.04) 5.6 x 10-55 1.5 x 10-54 
Triglyceridesb, mmol/L 1.32 (0.93) 0.37 (0.03) 9.4 x 10-33 1.5 x 10-32 
Total cholesterolb, mmol/L 5.59 (1.11) 0.57 (0.03) 9.4 x 10-64 7.5 x 10-63 
SBPc, mmHg 124.6 (19.33) 0.32 (0.04) 2.0 x 10-19 2.7 x 10-19 
DBPc, mmHg 75.09 (10.72) 0.26 (0.04) 8.1 x 10-16 9.3 x 10-16 
a Heritability estimates for body mass index; adjusted by age, age2, sex, sex*age, and sex*age2.  
b Heritability estimates for high density lipoprotein cholesterol, low density lipoprotein cholesterol, 
triglycerides and total cholesterol adjusted by age, age2, sex, sex*age, sex*age2 using lipid-lowering 
medication-adjusted values.  
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c Heritability estimates for systolic blood pressure and diastolic blood pressure adjusted by age, age2, sex, 
sex*age, sex*age2 using blood-pressure-lowering medication-adjusted values.  
Abbreviations: h2: narrow-sense heritability; SD: standard deviation; SE:Standard Error; HDL-C: high 
density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; BMI: body mass index; WHR: 
waist-hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure 
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Table 2: Heritabilities of lipid classesa  
Lipid Class 
(Abbreviated 
name) 
Lipid Class 
(Full name) 
n h2 (SE)b 
 
p-value 
 
q-value 
 
dhCer Dihydroceramide 6 0.35 (0.04) 9.5 x 10-27 2.4 x 10-26 
Cer(d) Ceramide 40 0.34 (0.04) 3.6 x 10-25 7.0 x 10-25 
HexCer Monohexosylceramide 14 0.50 (0.04) 7.2 x 10-47 1.2 x 10-45 
Hex2Cer Dihexosylceramide 10 0.45 (0.04) 3.1 x 10-42 3.4 x 10-41 
Hex3Cer Trihexosylceramide 6 0.43 (0.04) 2.5 x 10-35 2.0 x 10-34 
SM Sphingomyelin 36 0.36 (0.04) 4.4 x 10-27 1.2 x 10-26 
GM1 GM1 ganglioside 1 0.28 (0.04) 2.5 x 10
-18 3.2 x 10-18 
GM3 GM3 ganglioside 7 0.40 (0.04) 2.7 x 10
-29 1.0 x 10-28 
Sulf Sulfatide 6 0.40 (0.04) 1.8 x 10-32 1.2 x 10-31 
PC Phosphatidylcholine 68 0.36 (0.04) 8.1 x 10-26 1.7 x 10-25 
PC(O) Alkylphosphatidylcholine 21 0.34 (0.04) 5.5 x 10-25 1.0 x 10-24 
PC(P) Alkenylphosphatidylcholine 24 0.40 (0.04) 1.1 x 10-31 6.1 x 10-31 
LPC Lysophosphatidycholine 56 0.29 (0.04) 3.4 x 10-17 3.9 x 10-17 
LPC(O) Lysoalkylphosphatidylcholine 10 0.31 (0.04) 1.5 x 10-19 2.0 x 10-19 
LPC(P) Lysoalkenylphosphatidylcholine 4 0.33 (0.04) 4.2 x 10-24 6.9 x 10-24 
PE Phosphatidylethanolamine 36 0.34 (0.04) 7.3 x 10-26 1.6 x 10-25 
PE(O) Alkylphosphatidylethanolamine 14 0.27 (0.04) 1.7 x 10-17 2.0 x 10-17 
PE(P) Alkenylphosphatidylethanolamine 54 0.29 (0.04) 1.4 x 10-18 1.9 x 10-18 
LPE Lysophosphatidylethanolamine 14 0.38 (0.04) 8.1 x 10-30 3.3 x 10-29 
LPE(P) 
Lysoalkenylphosphatidylethanolamin
e 
4 
0.31 (0.04) 2.2 x 10-21 3.2 x 10-21 
PG Phosphatidylglycerol 4 0.36 (0.03) 3.7 x 10-31 1.7 x 10-30 
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PI Phosphatidylinositol 27 0.35 (0.04) 3.5 x 10-26 8.1 x 10-26 
LPI Lysophosphatidylinositol  8 0.27 (0.04) 3.4 x 10-16 3.8 x 10-16 
PS Phosphatidylserine 7 0.16 (0.03) 4.0 x 10-7 4.1 x 10-7 
COH Cholesterol 1 0.26 (0.04) 5.9 x 10-15 6.3x 10-15 
CE Cholesteryl ester 28 0.38 (0.04) 7.2 x 10-29 2.2 x 10-28 
DE Dehydrocholesterol ester 6 0.28 (0.04) 1.2 x 10-17 1.5 x 10-17 
oxCE Oxidized cholesteryl esters  2 0.14 (0.04) 7.1 x 10-6 7.1 x 10-6 
AC Acylcarnitine 14 0.48 (0.03) 2.0 x 10-50 6.6 x 10-49 
DG Diacylglycerol 20 0.31 (0.03) 1.3 x 10-22 2.1 x 10-22 
TG Triacylglycerol 44 0.32 (0.03) 1.6 x 10-24 2.7 x 10-24 
TG(O) Alkyl-diacylglycerol 3 0.37 (0.04) 6.4 x 10-29 2.1 x 10-28 
CoQ10 Ubiquinone 1 0.29 (0.04) 1.7 x 10-20 2.5 x 10-20 
Total  596    
Abbreviations: n: number of lipid species within class; h2: heritability; SE: standard error 
a Lipid classes presented in this table were calculated by summing the lipid species within each class. 
b Heritability estimates adjusted by age, age2, sex, sex*age, sex*age2 and using lipid-lowering medication-
adjusted values.  
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Figures 
Figure 1.   Heritability of the 33 lipid classes plotted against lipid class concentration (pmol/mL). Circles 
show the heritability estimates, with standard error bars.  Abbreviations: AC:Acylcarnitine; CE:Cholesteryl 
ester; Cer(d):Ceramide; COH:Cholesterol; CoQ10:Ubiquinone; DE:Dehydrocholesteryl ester; 
DG:Diacylglycerol; dhCer:Dihydroceramide; GM1:GM1 ganglioside; GM3:GM3 ganglioside; 
HexCer:Monohexosylceramide; Hex2Cer:Dihexosylceramide; Hex3Cer:Trihexosylceramide; 
LPC:Lysophosphatidycholine; LPC(O):Lysoalkylphosphatidylcholine; 
LPC(P):Lysoalkenylphosphatidylcholine; LPE:Lysophosphatidylethanolamine; 
LPE(P):Lysoalkenylphosphatidylethanolamine; LPI:Lysophosphatidylinositol; oxCE:Oxidized cholesteryl 
esters; PC:Phosphatidylcholine; PC(O):Alkylphosphatidylcholine; PC(P):Alkenylphosphatidylcholine; 
PE:Phosphatidylethanolamine; PE(O):Alkylphosphatidylethanolamine; 
PE(P):Alkenylphosphatidylethanolamine; PG:Phosphatidylglycerol; PI:Phosphatidylinositol; 
PS:Phosphatidylserine; SM:Sphingomyelin; Sulf:Sulfatide; TG:Triacylglycerol; TG(O):Alkyl-
diacylglycerol.  
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Figure 2.  Heritability of the 596 lipid species stratified by class, presented as a boxplot, indicating the 
median and 25th and 75th centiles with whiskers representing the upper and lower limits. Full heritability 
estimates are shown in Supplementary Table 1.  
Abbreviations: For lipids, please refer to abbreviations used in Figure 1. 
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Figure 3. Genetic correlation between 33 lipid classes and 8 CVD traits. Circles represent the genetic 
correlation, with bars indicating standard errors. Genetic correlations that are different from zero at a false 
discovery rate (FDR) of 0.05 are shown in black, and those not different from zero are shown in grey. Full 
genetic correlation estimates are shown in Supplementary Table 2.  
Abbreviations: For lipids, please refer to abbreviations used in Figure 1. BMI: body mass index; WHR: 
waist-hip ratio; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; 
TRIGS: triglycerides; TOTAL CHOL: total cholesterol; SBP: systolic blood pressure, DBP: diastolic blood 
pressure. 
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Figure 4. Heat map of genetic correlations between lipid species and cardiovascular disease traits. Red, negative genetic correlation; blue, positive genetic 
correlation. Only genetic correlations that are different from zero at a false discovery rate (FDR) of 0.05 are shown in the plot. Full genetic correlation 
estimates are shown in Supplementary Table 3.  
Abbreviations: For lipids and cardiovascular risk factors, please refer to abbreviations used in Figure 3. 
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